NASDAQ: NTRBNutriband Inc Stock
$5.05+0.02 (+0.4%)
Updated Apr 17, 2025
NTRB Price
$5.05
Fair Value Price
N/A
Market Cap
$56.09M
52 Week Low
$3.20
52 Week High
$11.78
P/E
-7.11x
P/B
4.99x
P/S
33.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.02M
Earnings
-$6.85M
Gross Margin
31.6%
Operating Margin
-336.65%
Profit Margin
-338.7%
Debt to Equity
0.12
Operating Cash Flow
-$4M
Beta
0.52
Next Earnings
Apr 28, 2025
Ex-Dividend
N/A
Next Dividend
N/A
NTRB Overview
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NTRB's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NTRB
Ranked#69 of 463
Ranked#69 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important NTRB news, forecast changes, insider trades & much more!
NTRB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NTRB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NTRB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NTRB is poor value based on its book value relative to its share price (4.99x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
NTRB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NTRB due diligence checks available for Premium users.
Valuation
NTRB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.11x
Industry
-177.72x
Market
27.98x
NTRB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.99x
Industry
4.05x
NTRB is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NTRB's financial health
Profit margin
Revenue
$645.8k
Net Income
-$1.4M
Profit Margin
-211%
NTRB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NTRB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$12.5M
Liabilities
$1.3M
Debt to equity
0.12
NTRB's short-term assets ($6.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NTRB's short-term assets ($6.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NTRB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NTRB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.0M
Investing
-$47.0k
Financing
-$5.2k
NTRB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NTRB vs Biotech Stocks
Nutriband Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.